143 related articles for article (PubMed ID: 16810202)
61. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
62. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
63. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Shalapour S; Zelmer A; Pfau M; Moderegger E; Costa-Blechschmidt C; van Landeghem FK; Taube T; Fichtner I; Bührer C; Henze G; Seeger K; Wellmann S
Clin Cancer Res; 2006 Sep; 12(18):5526-32. PubMed ID: 17000689
[TBL] [Abstract][Full Text] [Related]
64. Charting a path through resistance: histone deacetylase inhibitors for
Kugler E
Haematologica; 2024 Jun; 109(6):1643-1645. PubMed ID: 38356461
[No Abstract] [Full Text] [Related]
65. CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia.
Crazzolara R; Bernhard D
Leuk Lymphoma; 2005 Nov; 46(11):1545-51. PubMed ID: 16236608
[TBL] [Abstract][Full Text] [Related]
66. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
67. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Prince HM; Bishton M; Harrison S
Leuk Lymphoma; 2008 Mar; 49(3):385-7. PubMed ID: 18297514
[TBL] [Abstract][Full Text] [Related]
68. Interleukin-4 enhances the survival of severe combined immunodeficient mice engrafted with human B-cell precursor leukemia.
Mitchell PL; Clutterbuck RD; Powles RL; De Lord C; Morilla R; Hiorns LR; Titley J; Catovsky D; Millar JL
Blood; 1996 Jun; 87(11):4797-803. PubMed ID: 8639851
[TBL] [Abstract][Full Text] [Related]
69. RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia.
Holland M; Castro FV; Alexander S; Smith D; Liu J; Walker M; Bitton D; Mulryan K; Ashton G; Blaylock M; Bagley S; Connolly Y; Bridgeman J; Miller C; Krishnan S; Dempsey C; Masurekar A; Stern P; Whetton A; Saha V
Blood; 2011 Jul; 118(3):638-49. PubMed ID: 21606482
[TBL] [Abstract][Full Text] [Related]
70. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
71. Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice.
Milani M; Laranjeira AB; de Vasconcellos JF; Brandalise SR; Nowill AE; Yunes JA
PLoS One; 2015; 10(6):e0129298. PubMed ID: 26068922
[TBL] [Abstract][Full Text] [Related]
72. Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia.
Johnson SM; Dempsey C; Chadwick A; Harrison S; Liu J; Di Y; McGinn OJ; Fiorillo M; Sotgia F; Lisanti MP; Parihar M; Krishnan S; Saha V
Blood; 2016 Jul; 128(3):453-6. PubMed ID: 27099150
[No Abstract] [Full Text] [Related]
73. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
Townsend EC; Murakami MA; Christodoulou A; Christie AL; Köster J; DeSouza TA; Morgan EA; Kallgren SP; Liu H; Wu SC; Plana O; Montero J; Stevenson KE; Rao P; Vadhi R; Andreeff M; Armand P; Ballen KK; Barzaghi-Rinaudo P; Cahill S; Clark RA; Cooke VG; Davids MS; DeAngelo DJ; Dorfman DM; Eaton H; Ebert BL; Etchin J; Firestone B; Fisher DC; Freedman AS; Galinsky IA; Gao H; Garcia JS; Garnache-Ottou F; Graubert TA; Gutierrez A; Halilovic E; Harris MH; Herbert ZT; Horwitz SM; Inghirami G; Intlekofer AM; Ito M; Izraeli S; Jacobsen ED; Jacobson CA; Jeay S; Jeremias I; Kelliher MA; Koch R; Konopleva M; Kopp N; Kornblau SM; Kung AL; Kupper TS; LeBoeuf NR; LaCasce AS; Lees E; Li LS; Look AT; Murakami M; Muschen M; Neuberg D; Ng SY; Odejide OO; Orkin SH; Paquette RR; Place AE; Roderick JE; Ryan JA; Sallan SE; Shoji B; Silverman LB; Soiffer RJ; Steensma DP; Stegmaier K; Stone RM; Tamburini J; Thorner AR; van Hummelen P; Wadleigh M; Wiesmann M; Weng AP; Wuerthner JU; Williams DA; Wollison BM; Lane AA; Letai A; Bertagnolli MM; Ritz J; Brown M; Long H; Aster JC; Shipp MA; Griffin JD; Weinstock DM
Cancer Cell; 2016 Apr; 29(4):574-586. PubMed ID: 27070704
[TBL] [Abstract][Full Text] [Related]
74. In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B-cell precursors.
Myers DE; Chandan-Langlie M; Chelstrom LM; Uckun FM
Leuk Lymphoma; 1996 Jul; 22(3-4):259-64. PubMed ID: 8819074
[TBL] [Abstract][Full Text] [Related]
75. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells.
Cocco C; Canale S; Frasson C; Di Carlo E; Ognio E; Ribatti D; Prigione I; Basso G; Airoldi I
Blood; 2010 Nov; 116(19):3887-98. PubMed ID: 20671120
[TBL] [Abstract][Full Text] [Related]
76. Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model.
Zunino SJ; Storms DH; Newman JW; Pedersen TL; Keen CL; Ducore JM
Int J Oncol; 2012 Apr; 40(4):1277-84. PubMed ID: 22200740
[TBL] [Abstract][Full Text] [Related]
77. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.
Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H
Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192
[TBL] [Abstract][Full Text] [Related]
78. Synthesis and evaluation of 2-carboxy indole derivatives as potent and selective anti-leukemic agents.
Cury NM; Capitão RM; Almeida RDCB; Artico LL; Corrêa JR; Simão Dos Santos EF; Yunes JA; Correia CRD
Eur J Med Chem; 2019 Nov; 181():111570. PubMed ID: 31408809
[TBL] [Abstract][Full Text] [Related]
79. Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia.
Fulcher J; Leung E; Christou G; Bredeson C; Sabloff M
Leuk Lymphoma; 2020 Sep; 61(9):2271-2273. PubMed ID: 32427017
[No Abstract] [Full Text] [Related]
80. Cobalamin deficiency during treatment of pediatric precursor B-cell acute lymphoblastic leukemia.
Kinoshita H; Watanabe A; Taji Y; Yoshimura M; Ohta A; Fukushima T; Tanaka R; Ebihara Y
Pediatr Blood Cancer; 2021 Dec; 68(12):e29258. PubMed ID: 34302713
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
